SILOSilo Pharma, Inc.

Nasdaq silopharma.com


$ 2.14 $ -0.34 (-13.77 %)    

Tuesday, 30-Jul-2024 15:58:16 EDT
QQQ $ 455.87 $ -6.37 (-1.37 %)
DIA $ 407.51 $ 1.90 (0.47 %)
SPY $ 539.90 $ -2.76 (-0.51 %)
TLT $ 93.85 $ 0.36 (0.39 %)
GLD $ 222.54 $ 2.20 (1 %)
$ 2.13
$ 2.49 x 100
-- x --
-- - --
$ 0.84 - $ 4.50
711,532
na
5.97M
$ -13.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-25-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-24-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-01-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-29-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-20-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 04-04-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 04-02-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-17-2017 03-31-2017 10-Q
30 03-31-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 09-30-2016 06-30-2016 10-Q
33 08-31-2016 03-31-2016 10-Q
34 06-14-2016 12-31-2015 10-K
35 11-20-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 05-15-2015 03-31-2015 10-Q
38 03-31-2015 12-31-2014 10-K
39 11-14-2014 09-30-2014 10-Q
40 08-12-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 silo-pharma-proposes-21m-registered-direct-offering-of-763638-shares-of-common-stock-at-a-purchase-price-of-275-per-share-priced-at-the-market-under-nasdaq-rules

Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focu...

 silo-pharma-finds-partner-for-device-development-for-intranasal-ptsd-drug

Silo Pharma stock soared on high trading volume after announcing a partnership with Resyca BV for developing an intranasal PTSD...

 why-is-nano-cap-silo-pharma-stock-skyrocketing-on-tuesday

Silo Pharma shares surge due to a global license agreement for Alzheimer's drug SPC-14, aiming to utilize the FDA's 505...

Core News & Articles
Market-Moving News for July 16th
07/16/2024 12:40:58

SILO: 143% | Silo Pharma Obtains Exclusive Global License To Develop, Manufacture, And Commercialize Its Alzheimer's Drug G...

 silo-pharma-awarded-contract-to-its-contract-research-organization-partner-amplifybio-for-ind-enabling-large-animal-glp-study-of-spc-15-for-ptsd

Amplify Bio to complete GLP study of SPC-15 Novel Intranasal TherapeuticSilo study advances SPC-15 towards first-in-human trial

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION